Piper Sandler maintains Boston Scientific stock rating after device feedback By Investing.com

Boston Scientific's CHAMPION-AF trial met all primary and secondary endpoints but showed a slightly higher ischemic stroke rate versus NOACs; Watchman is expected by Piper Sandler to grow ~20% annually and add ~200bps to BSX top-line. BSX trades at $62.82 (near 52-week low $61.24), down ~35% over six months despite ~20% revenue growth and a PEG of ~0.58. UBS, Truist and RBC reiterated Buy/Outperform ratings with price targets of $105, $92 and $115 respectively, while Piper Sandler reiterated overweight on BSX and flagged tougher clinician education ahead; the firm remained cautious on Medtronic's other growth drivers.

Analysis

Broadcom (AVGO) is the durable winner in this tape even if headline AI deals land mainly with hyperscalers: the deal structure favors long-duration, high-margin silicon and switch revenue that converts into more predictable gross margin and FCF profile versus one-off server CPU cycles. That dynamic amplifies second-order pressure on legacy networking incumbents and smaller silicon vendors as hyperscalers consolidate on a narrower set of preferred suppliers, making AVGO a levered play on secular AI networking spend rather than a short-term earnings pop.

In cardiac devices, clinician adoption remains the gating factor and creates a wide outcome distribution over 6–24 months. The market is trading a binary: rapid clinician conversion and payer acceptance would re-rate survivable growth names; a persistent safety signal or slower real-world uptake would compress multiples quickly through both revenue misses and renewed headline risk (regulatory, reimbursement, litigation). Expect incremental data releases, registries, and guideline statements to move sentiment more than quarterly prints.

Put succinctly for trading: AVGO is a low-idiosyncratic-risk way to play AI infrastructure, while Boston Scientific (BSX) is a high-idiosyncratic-reward/binary name where conviction should be event-driven and hedged. Medtronic (MDT) is a candidate for short-duration hedge exposure to the device complex given execution questions on multiple growth engines. Position sizing and option structures should reflect the asymmetric information and timing uncertainty in the clinical adoption pathway.

Key Decisions for Investors

• Long AVGO 6–12 month call spread (buy 12-month 1x ITM call, sell 12-month 1.3x OTM call) — target 30–50% upside on spread if hyperscaler deployments accelerate; size as core overweight (3–5% portfolio). Rationale: converts AI/networking deal cadence into convex upside while capping cost; downside limited to premium paid if hyperscaler rollouts slip 3–9 months.
• Event-driven long BSX via 9–18 month call spread capped with a small out-of-the-money protective put (buy call spread + buy 1/3 notional put) — target asymmetric 2:1 reward:risk if adoption metrics or registries print supportive data in next 6–12 months. Keep position small (1–3% portfolio) and scale into confirmed uptake from multiple high-volume centers to avoid headline risk.
• Pair trade: small long BSX / short MDT (equal notional) for 3–9 month horizon — this isolates device-adoption upside vs. execution/portfolio-risk at MDT. Use tight stop if the pair diverges >12%; target pair return of 15–25% if BSX adoption surprises positively while MDT execution remains questioned.
• Tactical hedge: buy inexpensive 3–6 month index-protective put or raise cash if BSX/MDT headlines turn adverse — a 1–2% portfolio hedge is warranted given tail litigation/regulatory risk that could compress medtech multiples >20% within 3 months.
• Liquidity & triggers: enter AVGO spread on <5% pullback or on confirming hyperscaler incremental revenue commentary; enter BSX trades only on either a) multi-center real-world registry release showing neutral/positive ischemic outcomes or b) a >10% share-price pullback that reflects headline overreaction — both are 6–12 month catalysts.